Safety Communications: US FDA Panel Offers Menu Of Options For Singulair's Risks
Executive Summary
A common theme among the public speakers at the advisory committee was that their children's prescribers never informed them of the existing warning and precaution in the label. With that in mind, the US FDA now heads to the drawing board after a joint panel offers a series of options to more effectively communicate the potential neuropsychiatric risks associated with Singulair.
You may also be interested in...
US FDA Orders Singulair Boxed Warning On Neuropsychiatric Events Despite ‘Limited’ Evidence
Therapeutic alternatives and lack of prescriber and parent knowledge about existing warnings drove agency’s decision, despite internal concerns about the adequacy of the evidence to support the safety action.
'Dear Doctor Mom' – US FDA Urged To Find Way To Reach Pediatric Patient Parents With Safety Updates
How should FDA make sure new safety information gets widely disseminated – especially against a history of many communications that have not shown the sustained ability to reach the most active prescribers? The agency got an earful of suggestions from the most recent safety review of the asthma/allergy drug montelukast.
Black Box Appears Unlikely For Singulair Ahead Of US FDA Panel Review Of Pediatric Safety
US FDA seeking recommendations on further labeling and communication strategies for Merck's Singulair, which has long carried a risk of neuropsychiatric events, from the agency's Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee.